Vigpoder (vigabatrin) for oral solution has been made available by Pyros Pharmaceuticals for the treatment of:
- Refractory complex partial seizures as adjunctive therapy in patients 2 years of age and older who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss; it is not indicated as a first line agent; and.
- Infantile spasms as monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.
According to the Company, Vigpoder is therapeutically equivalent to Sabril® (vigabatrin) for oral solution. Like with other vigabatrin products, the prescribing information for Vigpoder includes a Boxed Warning regarding the risk of permanent vision loss. It is only available through the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program.
Vigpoder is supplied as 500mg packets in a 50-count carton. The product should be mixed with water prior to administration. Additional prescriber information can be accessed through the Pyros Total Care
program.
“The launch of Vigpoder and the Pyros Total Care program underscores our dedication to supporting families facing the challenges of infantile spasms,” said Michael Smith, CEO at Pyros. “We strive to elevate the overall treatment experience and offer comprehensive support to families navigating this challenging journey. Moreover, we are committed to initiatives aimed at accelerating symptom recognition and referrals to neurologists.”
Related Content
